CMMB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CMMB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Chemomab Therapeutics's tax expense for the months ended in Sep. 2024 was $0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.
The historical data trend for Chemomab Therapeutics's Tax Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Tax Expense | - | - | -0.53 | - |
Chemomab Therapeutics Quarterly Data | |||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Tax Expense | Get a 7-Day Free Trial | -0.06 | - | - | - | - |
Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.
Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemomab Therapeutics (NAS:CMMB) Tax Expense Explanation
In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.
Thank you for viewing the detailed overview of Chemomab Therapeutics's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Orbimed Israel Biofund Gp Limited Partnership | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
George Adi Mor | director, 10 percent owner, officer: Chief Executive Officer | 15 KAFRISIN ST., TEL AVIV L3 6901658 |
Neil Harris Cohen | director | C/O ANCHIANO THERAPEUTICS LTD., ONE KENDALL SQ., BLDG 1400E, STE 14-105, CAMBRIDGE MA 02139 |
Matthew Bejosa Frankel | officer: Chief Medical Officer | 672 PROSPECT AVE., PRINCETON NJ 08540 |
Jill M. Quigley | director | TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103 |
Joel Michael Maryles | director | 5 ATZMON ST., HASHMONAIM L3 7312700 |
Donald Marvin | officer: Executive VP, CFO & COO | 2094 LOST CANYON RANCH CT, CASTLE ROCK CO 80104 |
Dale R Pfost | director, officer: Chief Executive Officer | ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104 |
Nissim Darvish | director | C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Peter Thiel | 10 percent owner | 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069 |
Sigal Fatal | officer: Chief Financial Officer | 16 KANFEY NESHARIM ST., RAMAT GAN L3 5235716 |
Arnon Aharon | officer: Chief Medical Officer | 12 YAVNE ST., TEL AVIV L3 6579116 |
Alan Charles Moses | director | C/O 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002 |
Stephen P Squinto | director | C/O ALEXION PHARMACEUTICALS INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
Orbimed Israel Gp Ltd. | 10 percent owner | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
From GuruFocus
By Marketwired • 07-26-2024
By GuruFocus Research • 03-01-2024
By Marketwired • 08-28-2024
By Marketwired • 07-30-2024
By Marketwired • 10-30-2024
By PRNewswire • 03-07-2024
By Marketwired • 08-21-2024
By GuruFocus Research • 03-01-2024
By Marketwired • 07-25-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.